Prostate Cancer | Specialty

The prostate cancer condition center is a comprehensive resource for clinical news and expert insights on prostate cancer. Read more at OncLive.

Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age

December 6th 2025

Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

December 5th 2025

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Dr Smith on the Role of Radioligand Therapy in Prostate Cancer

December 4th 2025

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

Lutetium Lu 177 Vipivotide Tetraxetan Shows Activity in Oligometastatic HSPC

December 2nd 2025

Lutetium Lu 177 vipivotide tetraxetan was effective in patients with oligometastatic hormone-sensitive prostate cancer.

FDA Approves IsoPSA Blood-Based Prostate Cancer Test as Diagnostic Aid for High-Risk Disease

December 1st 2025

IsoPSA has been FDA approved for use as an aid in the diagnosis of high-grade prostate cancer in men at least 50 years of age with elevated PSA levels.

Dr Freedland on the Increasingly Prominent Role of Enzalutamide in Prostate Cancer Treatment

December 1st 2025

Stephen Freedland, MD, discusses how findings from the phase 3 EMBARK trial suggest a new standard of care in prostate cancer.

Dr Smith on Future Research Directions in Prostate Cancer

November 28th 2025

Matthew R. Smith, MD, PhD, discusses what the future of prostate cancer research may look like.

Dr Freedland on the Efficacy Results From the EMBARK Trial of Enzalutamide in Prostate Cancer

November 24th 2025

Stephen Freedland, MD, discusses how the efficacy findings of each arm of the phase 3 EMBARK trial in prostate cancer stacked up with one another.

Five Under 5: Top Oncology Videos for the Week of 11/16

November 23rd 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Dr Smith on the Role of Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

November 21st 2025

Matthew R. Smith, MD, PhD, discusses the role of darolutamide in mHSPC following its approval as monotherapy.

FDA Approves Osvyrti and Jubereq in High Fracture Risk Populations, Including in Breast and Prostate Cancer

November 20th 2025

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

Dr Freedland on the Rationale Behind the EMBARK Trial in Prostate Cancer

November 18th 2025

Stephen Freedland, MD, discusses the rationale for conducting the phase 3 EMBARK trial evaluating enzalutamide plus leuprolide in high-risk prostate cancer.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

PSMAddition Data Support Integration of Lutetium Lu 177 Vipivotide Tetraxetan into mHSPC Management

November 14th 2025

Scott Tagawa, MD, MS, FACP, FASCO, discusses data for lutetium Lu 177 vipivotide tetraxetan in mHSPC from the PSMAddition trial.

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

November 13th 2025

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Dr Tagawa on the Safety Profile of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 12th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the safety profile of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Tagawa on the Efficacy of Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

November 6th 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the efficacy of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Dr Saad on the Importance of Timing When Incorporating Radium-223 Into Prostate Cancer Treatment

October 29th 2025

Fred Saad, MD, discusses the importance of timing when incorporating radium-223 into prostate cancer treatment.